Nuubo — Series A (estimated) · €3M

'la Caixa' (through its Caixa Innvierte BioMed II fund) and CRB Inverbio (through CRB Bio II) co-led a €3M round. Existing main shareholder Fides Capital and new minority partners joined. The money was to push Nuubo into the main European markets, with 2014 sales expected to pass €1M. Sources describe the lead as joint, and Caixa Capital Risc is listed as lead here only because the field takes one name.

LeadCaixa Capital Risc (Caixa Innvierte BioMed II), CRB Inverbio (CRB Bio II) RoundSeries A (estimated) AnnouncedMay 2014 CityMadrid SectorHealthtech & Bio · Medtech / Wearables Source C

Something wrong? Suggest a correction →